March 6, 2014
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc., a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focused on DelMar Pharmaceuticals recent update on the company’s ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
“We find this trial update very encouraging, as DMPI remains on track with their dose-escalation study and overall clinical trial program for VAL-083. We anticipate DMPI advancing VAL-083 toward registration directed trials in refractory glioblastoma in 1H14E,” stated Ajay Tandon, CEO of SeeThruEquity.
The report is available to SeeThruEquity Select Members on SeeThruEquity’s website and can be directly accessed here:DMPI VAL-083 Update. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The report will also available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.